Le Lézard
Classified in: Health
Subjects: NPT, LEG

Susan G. Komen® Applauds Senate Committee for Advancing SCREENS For Cancer Act That Will Make Breast Health Services More Accessible


Urges U.S. Senate and House to Take Quick Action So Millions Can Get The Care They Need

WASHINGTON, Dec. 12, 2023 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, today commended members of the U.S. Senate Committee on Health, Education, Labor, and Pensions (HELP) for passing the Screening for Communities to Receive Early and Equitable Needed Services (SCREENS) for Cancer Act, an important step in the legislation becoming law. The full U.S. Senate and House will need to approve the legislation and President Joe Biden will need to sign it before it can become law.

Susan G. Komen applauds the advancement of federal legislation that would make breast health services more accessible.

The SCREENS for Cancer Act reauthorizes a critical program ? the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) ? that provides access to breast and cervical cancer screening and diagnostic services for low-income, uninsured or underinsured people in all 50 states, the District of Columbia, 2 U.S. territories, 5 U.S.-Affiliated Pacific Islands, and 13 tribes or tribal organizations.

Unfortunately, widespread racial health disparities persist in breast cancer, and NBCCEDP helps to address the barriers that lead to poor outcomes. 

The bicameral, bipartisan legislation is led by Senators Tammy Baldwin (D-WI), Susan Collins (R-ME), Catherine Cortez Masto (D-NV), Shelley Moore Capito (R-WV), and Amy Klobuchar (D-MN) and Representatives Jospeh Morelle (D-NY-25) and Brian Fitzpatrick (R-PA-01).

Since its founding in 1991, NBCCEDP-funded programs have served more than 6.2 million individuals across the country and provided more than 12.1 million breast and cervical cancer screening examinations.

"We cannot realize breast health equity without ensuring that timely screening and diagnostic services are available to all. These services are key to finding breast cancer early when more treatment options are available and patient outcomes are generally better, but too many barriers still prevent individuals from accessing routine breast care," said Victoria Smart, SVP of Mission at Susan G. Komen. "Komen is grateful the Senate HELP Committee has advanced the SCREENS for Cancer Act to expand the reach of the NBCCEDP by making screening and diagnostic services available to the people who need them, when they need them."

The NBCCEDP, a partnership between the Centers for Disease Control and Prevention (CDC) and state health departments, also provides public education, outreach, patient navigation and care coordination to increase breast and cervical cancer screening rates and reach underserved, vulnerable populations. The SCREENS for Cancer Act, once passed, will preserve access to this vital public health infrastructure and allow greater flexibility to NBCCEDP grantees, allowing for more emphasis on implementing innovative, evidence-based interventions and aggressive outreach through media, peer educators and patient navigators.

"It has been over a decade since Congress last revisited the underlying statute for NBCCEDP," Smart said. "Komen is proud to partner with distinguished Congressional champions to recommit to early detection and diagnosis and modernize a program with a long legacy of saving lives. We look forward to building on this momentum and seeing the SCREENS for Cancer Act passed by this Congress."

About Susan G. Komen®

Susan G. Komen® is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at www.komen.org/contact-us/follow-us/.

CONTACT: Amanda DeBard
Susan G. Komen
(972) 701-2131
[email protected] 

SOURCE Susan G. Komen for the Cure


These press releases may also interest you

at 11:03
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

at 08:35
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

at 07:05
Mirum Pharmaceuticals, Inc. today announced data presented during the 56th European Society for Paediatric, Gastroenterology, Hepatology, and Nutrition (ESPGHAN) Annual Meeting which took place this week in Milan, Italy. Data from LIVMARLI®...

at 07:00
Mallinckrodt plc, a global specialty pharmaceutical company, today announced the presentation of two posters on TERLIVAZ® (terlipressin) for injection in patients with hepatorenal syndrome (HRS) with rapid reduction in kidney function1 at the 2024...

17 mai 2024
Family Braces, Calgary's largest group of orthodontists with five locations across the city, reports a strong start to the second quarter of 2024. This positive momentum builds on the group's successful first quarter, underlining its...

17 mai 2024
American Skin Association (ASA) announced the recipients of the 2024 Inaugural Founders Award and the 2024 Research Achievement Awards at the 2024 Society for Investigative Dermatology (SID) Annual Meeting. ...



News published on and distributed by: